Session IV: Endpoint Analysis

Much has been learned from clinical trials in NASH that have already been performed. This session dives into those lessons learned relative to study design, histopathologic assessment and the utilization of AI digital pathology. Combination therapy for NASH will also be discussed. 

SPEAKERS

Moderators:
Veeral H. Ajmera, MD 
Michelle Long, MD, MSc

Presenters:
Cynthia A. Behling, MD, PhD - Refining Histopathologic Data Collection and Analysis
Mazen Noureddin, MD - Utilization of AI in Pathology in Clinical Trials in NASH and Cirrhosis
Michael R. Charlton, MD, FRCP - Combination Therapy and What Does the Future Look Like